Advancements in the Management of Ovarian Cancer - Episode 5
Overview of PRIMA - Niraparib 1L Maintenance
Panelists discuss the implications of PFS and OS data from the PRIMA trial evaluating niraparib as first-line maintenance therapy in advanced ovarian cancer, and the impact of these findings on the treatment paradigm, as well as new insights from the GEICO-88R study on long-term responders to niraparib. They also explore emerging maintenance strategies, including IO combination therapies and hormonal therapies, with a focus on ongoing trials such as rucaparib plus nivolumab, atezolizumab plus bevacizumab, and olaparib plus cediranib.
Video content above is prompted by the following:
- Dr Chan to ask Dr Herzog: Briefly comment on PFS and OS data from the PRIMA trial, evaluating niraparib first-line maintenance therapy in newly diagnosed advanced ovarian cancer.
- What implications do these findings have, and what impact may they have on the treatment paradigm for ovarian cancer?
- What new insights can be drawn about long-term responders to maintenance niraparib from the recent subanalysis of the GEICO-88R study?
Dr Herzog: What new maintenance strategies (eg, IO combination therapy or hormonal maintenance therapy) are being explored for advanced/metastatic disease?
- Dr Chan to address: Rucaparib plus nivolumab (Monk B, et al. ESMO 2024. Abs LBA30)
- Dr Herzog to address: Atezolizumab plus bevacizumab (Kurtz JE, et al. ESMO 2024. Abs 712MO)
- Dr Chan to address:Olaparib plus cediranib ( Nicum S, et al. ESMO 2024. LBA33)
- Dr Herzog to address: Other clinical trials that are being explored in combination therapy
Dr Herzog to ask Dr Chan: In which patients may you consider the above combination approaches?
Related Content:
